CY1112102T1 - Υποκατεστημενες πυριμιδοδιαζεπινες χρησιμες ως αναστολεις plk1 - Google Patents

Υποκατεστημενες πυριμιδοδιαζεπινες χρησιμες ως αναστολεις plk1

Info

Publication number
CY1112102T1
CY1112102T1 CY20111101174T CY111101174T CY1112102T1 CY 1112102 T1 CY1112102 T1 CY 1112102T1 CY 20111101174 T CY20111101174 T CY 20111101174T CY 111101174 T CY111101174 T CY 111101174T CY 1112102 T1 CY1112102 T1 CY 1112102T1
Authority
CY
Cyprus
Prior art keywords
plk1
pyramidodiazepine
suspensions
substituted
formula
Prior art date
Application number
CY20111101174T
Other languages
English (en)
Inventor
Jianping Cai
Shaoqing Chen
Xin-Jie Chu
Kang Le
Kin-Chun Thomas Luk
Peter Michael Wovkulich
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39415299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112102(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of CY1112102T1 publication Critical patent/CY1112102T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση δίδει ενώσεις αναστολέα PLK1 του τύπου (Ι):
CY20111101174T 2007-03-22 2011-11-30 Υποκατεστημενες πυριμιδοδιαζεπινες χρησιμες ως αναστολεις plk1 CY1112102T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91935807P 2007-03-22 2007-03-22
EP08717594A EP2139892B1 (en) 2007-03-22 2008-03-11 Substituted pyrimidodiazepines useful as plk1 inhibitors

Publications (1)

Publication Number Publication Date
CY1112102T1 true CY1112102T1 (el) 2015-11-04

Family

ID=39415299

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101174T CY1112102T1 (el) 2007-03-22 2011-11-30 Υποκατεστημενες πυριμιδοδιαζεπινες χρησιμες ως αναστολεις plk1

Country Status (24)

Country Link
US (1) US7517873B2 (el)
EP (1) EP2139892B1 (el)
JP (1) JP5087640B2 (el)
KR (1) KR101157848B1 (el)
CN (2) CN101636399B (el)
AR (1) AR065794A1 (el)
AT (1) ATE524472T1 (el)
AU (1) AU2008228303B2 (el)
BR (1) BRPI0809088A2 (el)
CA (1) CA2680757A1 (el)
CL (1) CL2008000785A1 (el)
CY (1) CY1112102T1 (el)
DK (1) DK2139892T3 (el)
ES (1) ES2371832T3 (el)
HK (1) HK1139936A1 (el)
HR (1) HRP20110807T1 (el)
IL (1) IL200617A (el)
MX (1) MX2009010034A (el)
PE (1) PE20120495A1 (el)
PL (1) PL2139892T3 (el)
PT (1) PT2139892E (el)
SI (1) SI2139892T1 (el)
TW (1) TWI363629B (el)
WO (1) WO2008113711A1 (el)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ583061A (en) 2007-08-15 2012-06-29 Vertex Pharma 4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
WO2009042711A1 (en) 2007-09-25 2009-04-02 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
PL2610256T3 (pl) 2007-09-28 2016-11-30 Pochodne pirymidyny jako inhibitory kinaz białkowych
US20090291938A1 (en) * 2007-11-19 2009-11-26 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
EP2303889A1 (en) 2008-06-18 2011-04-06 F. Hoffmann-La Roche AG Halo-substituted pyrimidodiazepines as plkl inhibitors
CN102272134B (zh) 2008-12-09 2013-10-16 吉里德科学公司 Toll样受体调节剂
EP3828185A3 (en) 2009-01-06 2021-09-01 Dana Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
JP5721706B2 (ja) 2009-06-17 2015-05-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルス複製の阻害剤
AU2010292102B2 (en) 2009-09-14 2015-04-09 Gilead Sciences, Inc. Modulators of Toll-like receptors
CN103492381A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP3738964A1 (en) * 2013-03-15 2020-11-18 Dana Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
WO2015013635A2 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
SI3421468T1 (sl) 2013-11-13 2021-03-31 Vertex Pharmaceuticals Incorporated Postopki za pripravo inhibitorjev replikacije virusov influence
CN105849100B (zh) 2013-11-13 2019-07-16 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
RU2016134947A (ru) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. Производные диаминопиримидин бензолсульфона и их применение
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
AU2015287773B2 (en) 2014-07-11 2018-03-29 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
CN115043840A (zh) 2014-09-16 2022-09-13 吉利德科学公司 制备toll样受体调节剂的方法
CN106715431A (zh) 2014-09-16 2017-05-24 吉利德科学公司 Toll样受体调节剂的固体形式
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
SG10202007099TA (en) 2015-09-11 2020-08-28 Dana Farber Cancer Inst Inc Acetamide thienotriazoldiazepines and uses thereof
CN114957291A (zh) 2015-11-25 2022-08-30 达纳-法伯癌症研究所股份有限公司 二价溴结构域抑制剂及其用途
KR20180132812A (ko) * 2016-04-07 2018-12-12 다나-파버 캔서 인스티튜트 인크. 피리미도-디아제피논 키나아제 스캐폴드 화합물 및 ｐｉ3ｋ-매개된 장애의 치료 방법
US20220378919A1 (en) * 2019-09-27 2022-12-01 Dana-Farber Cancer Institute, Inc. Erk5 degraders as therapeutics in cancer and inflammatory diseases
WO2021194319A1 (en) * 2020-03-27 2021-09-30 Uppthera Vanillin derivative compounds inducing selective degradation of plk1
WO2022145989A1 (ko) * 2020-12-31 2022-07-07 (주) 업테라 선택적 plk1 억제제로서의 피리미도디아제핀 유도체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020063854A (ko) * 1999-09-17 2002-08-05 애보트 게엠베하 운트 콤파니 카게 치료제로서의 키나제 억제제
CN1551881A (zh) * 2001-09-04 2004-12-01 ���ָ��Ӣ��ķ�������Ϲ�˾ 新颖二氢喋啶酮,其制备方法及作为药物组合物的用途
WO2007095188A2 (en) * 2006-02-14 2007-08-23 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
SI2139892T1 (sl) 2011-12-30
CL2008000785A1 (es) 2009-03-27
EP2139892B1 (en) 2011-09-14
US7517873B2 (en) 2009-04-14
US20080234255A1 (en) 2008-09-25
AR065794A1 (es) 2009-07-01
PE20120495A1 (es) 2012-05-12
KR101157848B1 (ko) 2012-07-11
IL200617A (en) 2014-02-27
CN101636399B (zh) 2012-04-18
CN101636399A (zh) 2010-01-27
WO2008113711A1 (en) 2008-09-25
IL200617A0 (en) 2010-05-17
PT2139892E (pt) 2011-11-21
DK2139892T3 (da) 2011-12-12
AU2008228303B2 (en) 2012-04-19
PL2139892T3 (pl) 2012-03-30
ES2371832T3 (es) 2012-01-10
TWI363629B (en) 2012-05-11
ATE524472T1 (de) 2011-09-15
CN102746175B (zh) 2014-01-15
KR20090119913A (ko) 2009-11-20
BRPI0809088A2 (pt) 2014-09-09
CA2680757A1 (en) 2008-09-25
AU2008228303A1 (en) 2008-09-25
JP5087640B2 (ja) 2012-12-05
JP2010521514A (ja) 2010-06-24
TW200843781A (en) 2008-11-16
HK1139936A1 (en) 2010-09-30
MX2009010034A (es) 2009-10-12
HRP20110807T1 (hr) 2011-12-31
CN102746175A (zh) 2012-10-24
EP2139892A1 (en) 2010-01-06

Similar Documents

Publication Publication Date Title
CY1112102T1 (el) Υποκατεστημενες πυριμιδοδιαζεπινες χρησιμες ως αναστολεις plk1
CY1119218T1 (el) Αναστολεις διυδροπυριδοφθαλαζινονης της πολυμερασης της πολυαδενοσφωσφορικης ριβοζης (parp)
EA200900945A1 (ru) Новый способ синтеза агомелатина
UY29612A1 (es) Compuestos quimicos ii
DK2364308T3 (da) Pyrazinforbindelser som inhibitorer af Phosphodiesterase 10
CY1113131T1 (el) Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
CY1112829T1 (el) Νεα μεθοδος συνθεσης για την αγομελατινη
CR20120295A (es) Triazolopiridinas
CY1112705T1 (el) Συντηγμενες κυκλικες ενωσεις
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
MA32938B1 (fr) Composes organiques
CY1112595T1 (el) Αμιδοφαινοξυινδαζολια χρησιμα ως αναστολεις του c-met
ATE400567T1 (de) Kinaseinhibitoren
CY1110010T1 (el) Πυριδιναμινοσουλφονυλ υποκατεστημενα βενζαμιδια ως αναστολεις κυτοχρωματος ρ450 3α4 (cyp3a4)
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
CY1109234T1 (el) Αναστολεις κινασης
CY1115094T1 (el) Νεα μεθοδος για την συνθεση (7-μεθοξυ-1-ναφθυλ) ακετονιτριλιου και εφαρμογη στην συνθεση αγομελατινης
EA201101675A1 (ru) Спироэпоксиды как промежуточные продукты синтеза
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
CY1111573T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
EA200702428A1 (ru) Способы получения 4-бифенилилазетидин-2-онов
EA200900944A1 (ru) Новый способ получения кристаллической формы v агомелатина
EA200801306A1 (ru) Сульфамоилсульфонатные пролекарства